1887
  1. Home
  2. Eurosurveillance
  3. Volume 21, Issue 22, 02/Jun/2016
  4. Article
Research article Open Access
Like 0
Download

Abstract

The hepatitis B virus (HBV) and hepatitis C virus (HCV) epidemics warrant a comprehensive response based on reliable population-level information about transmission, disease progression and disease burden, with national surveillance systems playing a major role. In order to shed light on the status of surveillance in countries of the World Health Organization (WHO) European Region outside of the European Union and European Economic Area (EU/EEA), we surveyed 18 countries in Central and Eastern Europe. Among the 10 countries that responded, the common features of many surveillance systems included mandatory surveillance, passive case-finding and the reporting of both acute and chronic HBV and HCV. Only some countries had surveillance systems that incorporated the tracking of associated conditions and outcomes such as cirrhosis and liver transplantation. Screening programmes for some key populations appeared to be in place in many countries, but there may be gaps in relation to screening programmes for people who inject drugs, prisoners, sex workers and men who have sex with men. Nonetheless, important components of a surveillance structure are in place in the responding study countries. It is advisable to build on this structure to develop harmonised HBV and HCV surveillance for all 53 Member States of the WHO European Region following the example of the system recently instituted in EU/EEA countries.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.22.30245
2016-06-02
2024-12-26
/content/10.2807/1560-7917.ES.2016.21.22.30245
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/22/eurosurv-21-22-1.html?itemId=/content/10.2807/1560-7917.ES.2016.21.22.30245&mimeType=html&fmt=ahah

References

  1. GBD 2013 Mortality and Causes of Death Collaborators; Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.  https://doi.org/10.1016/S0140-6736(14)61682-2  PMID: 25530442 
  2. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142(2):270-86.  https://doi.org/10.1017/S0950268813000940  PMID: 23714072 
  3. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.  https://doi.org/10.1016/S0140-6736(11)61097-0  PMID: 21802134 
  4. European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC, 2010.
  5. Hahné SJ, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13(1):181.  https://doi.org/10.1186/1471-2334-13-181  PMID: 23597411 
  6. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9(1):34.  https://doi.org/10.1186/1471-2458-9-34  PMID: 19161623 
  7. World Health Organization (WHO). Public health surveillance . Geneva: WHO. [Accessed 27 May 2015]. Available from: http://www.who.int/topics/public_health_surveillance/en/
  8. Nsubuga P, White ME, Thacker SB, Anderson MA, Blount SB, Broome CV, et al. Public Health Surveillance: A Tool for Targeting and Monitoring Interventions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease Control Priorities in Developing Countries. 2nd ed. Washington (DC): World Bank; 2006. [Accessed 27 May 2015]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11770/
  9. Committee on the Prevention and Control of Viral Hepatitis Infection; Board on Population Health and Public Health Practice; Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National. Academies Press; 2010. Available from: http://www.nap.edu/catalog/12793.html
  10. Wiktor SZ. Where next for hepatitis B and C surveillance? J Viral Hepat. 2015;22(7):571-3.  https://doi.org/10.1111/jvh.12400  PMID: 25754464 
  11. Rantala M, van de Laar MJW. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13(21):18880. PMID: 18761967 
  12. Duffell EF, van de Laar MJ. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009. Euro Surveill. 2015;20(13):17-24.  https://doi.org/10.2807/1560-7917.ES2015.20.13.21080  PMID: 25860392 
  13. World Health Organization (WHO). WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Geneva: WHO; 2003.
  14. Duffell EF, van de Laar MJW, Amato-Gauci AJ. Enhanced surveillance of hepatitis B in the EU, 2006-2012. J Viral Hepat. 2015;22(7):581-9.  https://doi.org/10.1111/jvh.12364  PMID: 25417854 
  15. Duffell EF, van de Laar MJW, Amato-Gauci AJ. Enhanced surveillance of hepatitis C in the EU, 2006 - 2012. J Viral Hepat. 2015;22(7):590-5.  https://doi.org/10.1111/jvh.12367  PMID: 25420699 
  16. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci. 2012;16(11):1473-83. PMID: 23111959 
  17. Punzalan CS, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat. 2015;22(10):769-76.  https://doi.org/10.1111/jvh.12399  PMID: 25754333 
  18. Sixty seventh World Health Assembly. WHA67.6 Hepatitis. 2014. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf
  19. World Health Organization (WHO). Development of the Global Health Sector Strategy on viral hepatitis, 2016-2021. Geneva: WHO. Available from: http://www.who.int/hiv/mediacentre/news/hepstrategy2016-21/en/
Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Antons+Mozalevskis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mozalevskis Antons</a>, <a href="/search?value1=Irina+Eramova&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Eramova Irina</a>, <a href="/search?value1=Kelly+Safreed-Harmon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Safreed-Harmon Kelly</a>, <a href="/search?value1=Jeffrey+V+Lazarus&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lazarus Jeffrey V</a></span>. Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012. <a href="/content/ecdc">Euro Surveill.</a> 2016;21(22):pii=30245. <a href="https://doi.org/10.2807/1560-7917.ES.2016.21.22.30245" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2016.21.22.30245</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 21 Sept 2015;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Jun 2016 </span> </p>
/content/10.2807/1560-7917.ES.2016.21.22.30245
/content/10.2807/1560-7917.ES.2016.21.22.30245
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error